Cargando…
Clinical and Immunological Phenotype of Patients With Primary Immunodeficiency Due to Damaging Mutations in NFKB2
Non-canonical NF-κB-pathway signaling is integral in immunoregulation. Heterozygous mutations in NFKB2 have recently been established as a molecular cause of common variable immunodeficiency (CVID) and DAVID-syndrome, a rare condition combining deficiency of anterior pituitary hormone with CVID. Her...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435015/ https://www.ncbi.nlm.nih.gov/pubmed/30941118 http://dx.doi.org/10.3389/fimmu.2019.00297 |
_version_ | 1783406582944497664 |
---|---|
author | Klemann, Christian Camacho-Ordonez, Nadezhda Yang, Linlin Eskandarian, Zoya Rojas-Restrepo, Jessica L. Frede, Natalie Bulashevska, Alla Heeg, Maximilian Al-Ddafari, Moudjahed Saleh Premm, Julian Seidl, Maximilian Ammann, Sandra Sherkat, Roya Radhakrishnan, Nita Warnatz, Klaus Unger, Susanne Kobbe, Robin Hüfner, Anja Leahy, T. Ronan Ip, Winnie Burns, Siobhan O. Fliegauf, Manfred Grimbacher, Bodo |
author_facet | Klemann, Christian Camacho-Ordonez, Nadezhda Yang, Linlin Eskandarian, Zoya Rojas-Restrepo, Jessica L. Frede, Natalie Bulashevska, Alla Heeg, Maximilian Al-Ddafari, Moudjahed Saleh Premm, Julian Seidl, Maximilian Ammann, Sandra Sherkat, Roya Radhakrishnan, Nita Warnatz, Klaus Unger, Susanne Kobbe, Robin Hüfner, Anja Leahy, T. Ronan Ip, Winnie Burns, Siobhan O. Fliegauf, Manfred Grimbacher, Bodo |
author_sort | Klemann, Christian |
collection | PubMed |
description | Non-canonical NF-κB-pathway signaling is integral in immunoregulation. Heterozygous mutations in NFKB2 have recently been established as a molecular cause of common variable immunodeficiency (CVID) and DAVID-syndrome, a rare condition combining deficiency of anterior pituitary hormone with CVID. Here, we investigate 15 previously unreported patients with primary immunodeficiency (PID) from eleven unrelated families with heterozygous NFKB2-mutations including eight patients with the common p.Arg853(*) nonsense mutation and five patients harboring unique novel C-terminal truncating mutations. In addition, we describe the clinical phenotype of two patients with proximal truncating mutations. Cohort analysis extended to all 35 previously published NFKB2-cases revealed occurrence of early-onset PID in 46/50 patients (mean age of onset 5.9 years, median 4.0 years). ACTH-deficiency occurred in 44%. Three mutation carriers have deceased, four developed malignancies. Only two mutation carriers were clinically asymptomatic. In contrast to typical CVID, most patients suffered from early-onset and severe disease manifestations, including clinical signs of T cell dysfunction e.g., chronic-viral or opportunistic infections. In addition, 80% of patients suffered from (predominately T cell mediated) autoimmune (AI) phenomena (alopecia > various lymphocytic organ-infiltration > diarrhea > arthritis > AI-cytopenia). Unlike in other forms of CVID, auto-antibodies or lymphoproliferation were not common hallmarks of disease. Immunophenotyping showed largely normal or even increased quantities of naïve and memory CD4(+) or CD8(+) T-cells and normal T-cell proliferation. NK-cell number and function were also normal. In contrast, impaired B-cell differentiation and hypogammaglobinemia were consistent features of NFKB2-associated disease. In addition, an array of lymphocyte subpopulations, such as regulatory T cell, Th17-, cTFH-, NKT-, and MAIT-cell numbers were decreased. We conclude that heterozygous damaging mutations in NFKB2 represent a distinct PID entity exceeding the usual clinical spectrum of CVID. Impairment of the non-canonical NF-κB pathways affects function and differentiation of numerous lymphocyte-subpopulations and thus causes a heterogeneous, more severe form of PID phenotype with early-onset. Further characteristic features are multifaceted, primarily T cell-mediated autoimmunity, such as alopecia, lymphocytic organ infiltration, and in addition frequently ACTH-deficiency. |
format | Online Article Text |
id | pubmed-6435015 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-64350152019-04-02 Clinical and Immunological Phenotype of Patients With Primary Immunodeficiency Due to Damaging Mutations in NFKB2 Klemann, Christian Camacho-Ordonez, Nadezhda Yang, Linlin Eskandarian, Zoya Rojas-Restrepo, Jessica L. Frede, Natalie Bulashevska, Alla Heeg, Maximilian Al-Ddafari, Moudjahed Saleh Premm, Julian Seidl, Maximilian Ammann, Sandra Sherkat, Roya Radhakrishnan, Nita Warnatz, Klaus Unger, Susanne Kobbe, Robin Hüfner, Anja Leahy, T. Ronan Ip, Winnie Burns, Siobhan O. Fliegauf, Manfred Grimbacher, Bodo Front Immunol Immunology Non-canonical NF-κB-pathway signaling is integral in immunoregulation. Heterozygous mutations in NFKB2 have recently been established as a molecular cause of common variable immunodeficiency (CVID) and DAVID-syndrome, a rare condition combining deficiency of anterior pituitary hormone with CVID. Here, we investigate 15 previously unreported patients with primary immunodeficiency (PID) from eleven unrelated families with heterozygous NFKB2-mutations including eight patients with the common p.Arg853(*) nonsense mutation and five patients harboring unique novel C-terminal truncating mutations. In addition, we describe the clinical phenotype of two patients with proximal truncating mutations. Cohort analysis extended to all 35 previously published NFKB2-cases revealed occurrence of early-onset PID in 46/50 patients (mean age of onset 5.9 years, median 4.0 years). ACTH-deficiency occurred in 44%. Three mutation carriers have deceased, four developed malignancies. Only two mutation carriers were clinically asymptomatic. In contrast to typical CVID, most patients suffered from early-onset and severe disease manifestations, including clinical signs of T cell dysfunction e.g., chronic-viral or opportunistic infections. In addition, 80% of patients suffered from (predominately T cell mediated) autoimmune (AI) phenomena (alopecia > various lymphocytic organ-infiltration > diarrhea > arthritis > AI-cytopenia). Unlike in other forms of CVID, auto-antibodies or lymphoproliferation were not common hallmarks of disease. Immunophenotyping showed largely normal or even increased quantities of naïve and memory CD4(+) or CD8(+) T-cells and normal T-cell proliferation. NK-cell number and function were also normal. In contrast, impaired B-cell differentiation and hypogammaglobinemia were consistent features of NFKB2-associated disease. In addition, an array of lymphocyte subpopulations, such as regulatory T cell, Th17-, cTFH-, NKT-, and MAIT-cell numbers were decreased. We conclude that heterozygous damaging mutations in NFKB2 represent a distinct PID entity exceeding the usual clinical spectrum of CVID. Impairment of the non-canonical NF-κB pathways affects function and differentiation of numerous lymphocyte-subpopulations and thus causes a heterogeneous, more severe form of PID phenotype with early-onset. Further characteristic features are multifaceted, primarily T cell-mediated autoimmunity, such as alopecia, lymphocytic organ infiltration, and in addition frequently ACTH-deficiency. Frontiers Media S.A. 2019-03-19 /pmc/articles/PMC6435015/ /pubmed/30941118 http://dx.doi.org/10.3389/fimmu.2019.00297 Text en Copyright © 2019 Klemann, Camacho-Ordonez, Yang, Eskandarian, Rojas-Restrepo, Frede, Bulashevska, Heeg, Al-Ddafari, Premm, Seidl, Ammann, Sherkat, Radhakrishnan, Warnatz, Unger, Kobbe, Hüfner, Leahy, Ip, Burns, Fliegauf and Grimbacher. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Klemann, Christian Camacho-Ordonez, Nadezhda Yang, Linlin Eskandarian, Zoya Rojas-Restrepo, Jessica L. Frede, Natalie Bulashevska, Alla Heeg, Maximilian Al-Ddafari, Moudjahed Saleh Premm, Julian Seidl, Maximilian Ammann, Sandra Sherkat, Roya Radhakrishnan, Nita Warnatz, Klaus Unger, Susanne Kobbe, Robin Hüfner, Anja Leahy, T. Ronan Ip, Winnie Burns, Siobhan O. Fliegauf, Manfred Grimbacher, Bodo Clinical and Immunological Phenotype of Patients With Primary Immunodeficiency Due to Damaging Mutations in NFKB2 |
title | Clinical and Immunological Phenotype of Patients With Primary Immunodeficiency Due to Damaging Mutations in NFKB2 |
title_full | Clinical and Immunological Phenotype of Patients With Primary Immunodeficiency Due to Damaging Mutations in NFKB2 |
title_fullStr | Clinical and Immunological Phenotype of Patients With Primary Immunodeficiency Due to Damaging Mutations in NFKB2 |
title_full_unstemmed | Clinical and Immunological Phenotype of Patients With Primary Immunodeficiency Due to Damaging Mutations in NFKB2 |
title_short | Clinical and Immunological Phenotype of Patients With Primary Immunodeficiency Due to Damaging Mutations in NFKB2 |
title_sort | clinical and immunological phenotype of patients with primary immunodeficiency due to damaging mutations in nfkb2 |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435015/ https://www.ncbi.nlm.nih.gov/pubmed/30941118 http://dx.doi.org/10.3389/fimmu.2019.00297 |
work_keys_str_mv | AT klemannchristian clinicalandimmunologicalphenotypeofpatientswithprimaryimmunodeficiencyduetodamagingmutationsinnfkb2 AT camachoordoneznadezhda clinicalandimmunologicalphenotypeofpatientswithprimaryimmunodeficiencyduetodamagingmutationsinnfkb2 AT yanglinlin clinicalandimmunologicalphenotypeofpatientswithprimaryimmunodeficiencyduetodamagingmutationsinnfkb2 AT eskandarianzoya clinicalandimmunologicalphenotypeofpatientswithprimaryimmunodeficiencyduetodamagingmutationsinnfkb2 AT rojasrestrepojessical clinicalandimmunologicalphenotypeofpatientswithprimaryimmunodeficiencyduetodamagingmutationsinnfkb2 AT fredenatalie clinicalandimmunologicalphenotypeofpatientswithprimaryimmunodeficiencyduetodamagingmutationsinnfkb2 AT bulashevskaalla clinicalandimmunologicalphenotypeofpatientswithprimaryimmunodeficiencyduetodamagingmutationsinnfkb2 AT heegmaximilian clinicalandimmunologicalphenotypeofpatientswithprimaryimmunodeficiencyduetodamagingmutationsinnfkb2 AT alddafarimoudjahedsaleh clinicalandimmunologicalphenotypeofpatientswithprimaryimmunodeficiencyduetodamagingmutationsinnfkb2 AT premmjulian clinicalandimmunologicalphenotypeofpatientswithprimaryimmunodeficiencyduetodamagingmutationsinnfkb2 AT seidlmaximilian clinicalandimmunologicalphenotypeofpatientswithprimaryimmunodeficiencyduetodamagingmutationsinnfkb2 AT ammannsandra clinicalandimmunologicalphenotypeofpatientswithprimaryimmunodeficiencyduetodamagingmutationsinnfkb2 AT sherkatroya clinicalandimmunologicalphenotypeofpatientswithprimaryimmunodeficiencyduetodamagingmutationsinnfkb2 AT radhakrishnannita clinicalandimmunologicalphenotypeofpatientswithprimaryimmunodeficiencyduetodamagingmutationsinnfkb2 AT warnatzklaus clinicalandimmunologicalphenotypeofpatientswithprimaryimmunodeficiencyduetodamagingmutationsinnfkb2 AT ungersusanne clinicalandimmunologicalphenotypeofpatientswithprimaryimmunodeficiencyduetodamagingmutationsinnfkb2 AT kobberobin clinicalandimmunologicalphenotypeofpatientswithprimaryimmunodeficiencyduetodamagingmutationsinnfkb2 AT hufneranja clinicalandimmunologicalphenotypeofpatientswithprimaryimmunodeficiencyduetodamagingmutationsinnfkb2 AT leahytronan clinicalandimmunologicalphenotypeofpatientswithprimaryimmunodeficiencyduetodamagingmutationsinnfkb2 AT ipwinnie clinicalandimmunologicalphenotypeofpatientswithprimaryimmunodeficiencyduetodamagingmutationsinnfkb2 AT burnssiobhano clinicalandimmunologicalphenotypeofpatientswithprimaryimmunodeficiencyduetodamagingmutationsinnfkb2 AT fliegaufmanfred clinicalandimmunologicalphenotypeofpatientswithprimaryimmunodeficiencyduetodamagingmutationsinnfkb2 AT grimbacherbodo clinicalandimmunologicalphenotypeofpatientswithprimaryimmunodeficiencyduetodamagingmutationsinnfkb2 |